(5,6-dimethyl-pyrimidin-4-yl)-methyl-amine | 52698-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (5,6-dimethyl-pyrimidin-4-yl)-methyl-amine
• 英文别名: N,5,6-Trimethylpyrimidin-4-amine
• CAS: 52698-58-5
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: DPALXMARPIMVEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  266.7±35.0 °C(Predicted)
• 密度：
  1.072±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013078254A1

  公开（公告）日：2013-05-30

  The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula 1: wherein Het, X, R1 and R2 are as defined herein.

  本发明提供了化合物，包括已分离的对映体、已分离的异构体、溶剂合物和其药学上可接受的盐，其化学式如下：其中Het、X、R1和R2的定义如本文所述。
• [EN] CARM1 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CARM1 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014144169A1

  公开（公告）日：2014-09-18

  Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic heteroaryl ring system of Formula (II) wherein L2, R13, G8, G10, G11, and G12 are as defined herein. Compounds of the present invention are useful for inhibiting CARMl activity. Methods of using the compounds for treating CARM1 -mediated disorders are also described.

  本文提供了式（I）的化合物及其药用盐，以及药物组合物；其中X、R1、R1a、R2a、R2b、R2c、R2d如本文所定义，环HET是式（II）的6-成员单环杂环芳基环系统，其中L2、R13、G8、G10、G11和G12如本文所定义。本发明的化合物可用于抑制CARM1活性。还描述了使用这些化合物治疗CARM1介导的疾病的方法。
• CHEMICAL COMPOUNDS AND PROCESSES
  申请人：Flynn Bernard Luke

  公开号：US20100048591A1

  公开（公告）日：2010-02-25

  The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which may possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.

  本发明一般涉及化合物和其使用和制备的方法。具体而言，本发明涉及可能具有有用治疗活性的化合物，这些化合物在治疗方法中的使用，以及制造药物和含有这些化合物的组合物。
• Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
  申请人：ModernaTX, Inc.

  公开号：US10258698B2

  公开（公告）日：2019-04-16

  The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

  本公开特别提供了包含修饰核酸分子的制剂组合物，修饰核酸分子可编码蛋白质、蛋白质前体或蛋白质或蛋白质前体的部分或完全加工形式。制剂组合物可进一步包括修饰的核酸分子和递送剂。本发明进一步提供了用于编码能够调节细胞功能和/或活性的多肽的核酸。
• [EN] CYCLIC DINUCLEOTIDE STING AGONISTS TETHERED TO A PD-1 OR CTLA-4 ANTIBODIES<br/>[FR] AGONISTES DE STING DINUCLÉOTIDIQUES CYCLIQUES ATTACHÉS À UN PD-1 OU À DES ANTICORPS CTLA-4
  申请人：SPEROVIE BIOSCIENCES INC

  公开号：WO2021046426A9

  公开（公告）日：2022-02-17